GlobeNewswire

Preclinical Studies Demonstrate Galimedix Therapeutics’ Investigational Compound GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Models

Del

Poster Presented at the Association for Research in Vision and Ophthalmology Annual Meeting

KENSINGTON, Md. and SHORASHIM, Israel, May 08, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today presented data demonstrating its novel, first-in-class, investigational compound GAL-101 provides neuroprotection from misfolded amyloid beta molecules aggregating into toxic forms in vitro, neutralizing their ability to be toxic to neural tissues.  Further, investigators discovered that peak levels from a single delivery of the compound may provide sustained detoxification.  The poster was presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Vancouver, British Columbia, Canada from April 28 to May 2, 2019.

“The unique mechanism of action of GAL-101 has been shown to reduce the levels of amyloid beta present in the retina, thereby both preventing neurodegeneration and increasing the chances of preventing vision loss.  However, this poster further demonstrates that a single peak administration of the compound by eye drops may also provide a sustained detoxifying effect in dry AMD and glaucoma patients,” commented Dr. Hermann Russ, lead author of the paper and Chief Scientific Officer of Galimedix.  “These preclinical data, combined with a positive result in the Phase 1 study have made it possible for us to move rapidly toward a Phase 2 program for which we will provide updates when available.” 

In the poster, investigators reported that eye drops of GAL-101 in repeated monkey models resulted in concentrations in the retina rapidly reaching levels far in excess of the threshold for initiating the peak-related pharmacological effect, and remained in those levels for at least four hours.  Furthermore, in age-related macular degeneration (AMD) mouse models with substantial amyloid beta deposits in the retina accumulated during many months, GAL-101 eye drops when given for 1-3 months resulted in substantially less amyloid beta deposits, and simultaneously reduced the levels of C-complement response, which is considered a central factor leading to the progression of dry AMD.

About GAL-101
GAL-101 is a proprietary compound designed to prevent the formation of all forms of toxic amyloid beta oligomers, by binding with high affinity to the misfolded amyloid beta monomers before they can form toxic soluble oligomers.  These then rapidly conglomerate into amorphous, non-beta-sheet formations, which we call “clusters,” which are innocuous.  Interestingly, once GAL-101 concentration reaches effective levels it “triggers” formation of the “clusters”, which then have shown the capacity to collect additional misfolded amyloid beta monomers even in the absence of additional GAL-101 molecules, through a self-propagation mechanism.  This novel “trigger effect,” protected by Galimedix’ patent portfolio, results in a sustained effect lasting far longer than the time a single administration of the drug remains at therapeutic levels in the retina, potentially allowing for a convenient interval application regimen for patients. Thus, GAL-101 drops may potentially provide sustained prevention of formation of toxic amyloid beta oligomers in the retina, leading to a reduction of complement response and their consequent damage.  Thus GAL-101 could contribute to slowing or stopping progression, and possible restoration of neural function depressed by the chronic toxic attack.

About Galimedix
Based in the United States and Israel, Galimedix is a Phase 2 ready ophthalmic pharmaceutical company with a world class drug development team advancing a novel, patented small molecule drug with a novel MOA addressing glaucoma and dry AMD utilizing an eye drops delivery platform, which may offer significant safety and compliance advantages over commonly used direct ocular injections.  Eye drops are used to deliver steroids and other small molecules, like GAL-101, to the retina, and studies with Galimedix’s eye drops in monkeys have demonstrated therapeutic levels quickly reaching the retina of the closest model to humans.  Compelling efficacy data from GAL-101 eye drops in relevant animal models have demonstrated more than 90 percent neuroprotection, and the compound is supported by several leading experts in glaucoma and in dry AMD who also support the design of the company’s proposed Phase 2 studies.

Galimedix has exclusive worldwide license from Tel Aviv University, following return of license by a German pharma (Merz) due to management change and strategic pivot away from neuroscience.  The license also includes a next generation, potentially superior molecule intended for oral delivery, with potential to treat retinal and other CNS diseases.    

Contact:
Jules Abraham
Core IR
julesa@coreir.com
917-885-7378

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Governance reform could see African economies benefit to tune of £23bn - PwC Global Economy Watch20.5.2019 12:00:00 CESTPressemelding

Continent-wide analysis of African economies demonstrates positive correlation between economic growth and rising governance indicators Ethiopia and Cote d’Ivoire demonstrate consistent annual average real per-capita growth of >5% since 2013 Particularly strong growth among East African economies (average 3% per capita), while Central Africa has struggled (fall by average 1.3%) Global analysis highlights slowdown in manufacturing sector linked to US-China trade war LONDON, May 20, 2019 (GLOBE NEWSWIRE) -- The latest edition of PwC’s bimonthly Global Economy Watch has found that African economies could receive a windfall of £23bn if each economy applied similar governance reforms equivalent to those made by Cote d’Ivoire since 2013. The continent-wide economic analysis modelled the performance of each country across six of the World Bank’s Worldwide Governance Indicators (2013-17), which covers aspects such as regulatory quality, rule of law and government effectiveness. The analysis ha

Levine Leichtman Capital Partners Promotes Monty Ismail to Senior Associate20.5.2019 11:00:00 CESTPressemelding

LOS ANGELES, May 20, 2019 (GLOBE NEWSWIRE) -- Levine Leichtman Capital Partners (“LLCP”), a Los Angeles-based private equity firm, is pleased to announce the promotion of Monty Ismail to Senior Associate. Mr. Ismail joined the London office of Levine Leichtman Capital Partners in 2018. Since that time, he has participated in several successful transactions, including the add-on acquisition of Globe Business Media Group for Law Business Research Ltd. and the recent acquisition of SK AeroSafety. As a dedicated member of the firm’s Structured Equity investment team, he will continue to monitor LLCP portfolio companies as well as be responsible for investment due diligence and analysis of new investment opportunities. “Monty has been an important member of the Levine Leichtman Capital Partners team. He has contributed significantly to the success of our London office and we are excited for his continued growth within the firm,” said Lauren Leichtman, LLCP’s co-founder. For more information

WindSim Names Donna Rennemo Chief Executive Officer20.5.2019 11:00:00 CESTPressemelding

TONSBERG, Norway and WESTLAKE VILLAGE, Calif., May 20, 2019 (GLOBE NEWSWIRE) -- WindSim AS, the leading provider and pioneer of CFD (Computational Fluid Dynamics) based Wind Farm Design Tools (WFDT) utilized for the design of wind farms both onshore and offshore, has today announced that its board of directors has appointed Donna Rennemo as president and chief executive officer. This leadership appointment is effective immediately and follow the Board of Directors in WindSim and John Olaf Rømma agreement to step down as the company’s CEO. “We are fortunate to have someone of Donna Rennemo’s caliber and experience to step up to lead WindSim,” said Dag Honningsvåg, WindSim Chairman of the Board. “We are at a critical moment and we need renewed leadership to successfully implement our strategy and take advantage of the market opportunities ahead. Rennemo is a technology visionary with a proven track record of execution. She is a strong communicator who is customer focused with deep leader

TransCanna Executes LOI To Acquire The Business and Assets of Premier Indoor Cultivator Lyfted Farms20.5.2019 09:05:00 CESTPressemelding

VANCOUVER, British Columbia, May 20, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – TransCanna Holdings Inc. (CSE:TCAN: XETR: TH8) (“TransCanna” or the “Company”) is pleased to announce the execution of a non-binding Letter Of Intent dated May 17, 2019 (the “LOI”) with Lyfted Farms, Inc. (“Lyfted”), of Modesto, California, to acquire the business and assets of Lyfted (the “Proposed Acquisition”). Lyfted Farms is a state licensed producer of high quality indoor grown cannabis. The three permanent state licenses that Lyfted owns are for cultivation (nursery), cultivation (grow), and distribution. “The Proposed Acquisition includes an exceptional brand, with a range of high-end flower, growing revenues, fifty exotic and unique genetic strains and a team that’s been a staple in the Modesto valley with over two decades of cultivating experience. In short, this is another example of an ideal acquisition candidate for TransCanna that offers SKU velocity, growing revenues and branded products that

Fortuna CEO purchases company shares17.5.2019 21:00:00 CESTPressemelding

VANCOUVER, British Columbia, May 17, 2019 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) reports that Jorge A. Ganoza, Chief Executive Officer of the Company, has increased his equity position in the Company by acquiring 170,000 common shares on the open market at an average price of US$2.59 per share. An insider report filing reflecting the share acquisition has been made on the SEDI website at www.sedi.ca. About Fortuna Silver Mines Inc. Fortuna is a growth oriented, precious metal producer with its primary assets being the Caylloma silver mine in southern Peru, the San Jose silver-gold mine in Mexico and the Lindero gold Project, currently under construction, in Argentina. The Company is selectively pursuing acquisition opportunities throughout the Americas and in select other areas. For more information, please visit its website at www.fortunasilver.com. ON BEHALF OF THE COMPANY Carlos Baca Investor Relations Manager Trading symbols: NYSE: FSM | TSX: FVI Inves

Oxford Immunotec Welcomes Updated CDC Recommendations for Tuberculosis Screening and Testing of Healthcare Personnel17.5.2019 15:25:00 CESTPressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., May 17, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it welcomes the updated Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019, published by the U.S. Centers for Disease Control and Prevention (CDC)1. These guidelines increase the focus on eradicating tuberculosis (TB) disease in the United States through an individual risk-based approach to screening and treatment for Healthcare Personnel (HCP). Key highlights from the updated guidelines include: Recommendation for TB Screening and Individual Based TB Risk Assessment on Hire : continue baseline screening of all HCPs upon hire with the addition of an individual risk assessment Recommendation to Focus Serial Testing on Higher Risk Individuals: decision to perform TB testing afte